Analysts have recently evaluated Neurocrine Biosciences and provided 12-month price targets. The average target is $179.83, ...

Huntington's disease symptom control relies on medications for involuntary movements, mood, and psychiatric symptoms, but ...

Symptoms caused by Huntington's disease include loss of motor control, involuntary movements, dementia, mood disorders, and psychiatric though disturbances.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.

Non-traumatic musculoskeletal disorders significantly impact the physical development, functional independence, and overall ...

New Neurocrine INGREZZA data reveals nearly two-fold higher target occupancy vs. AUSTEDO XR. This reinforces its competitive ...